Lupin announced the receipt of the Establishment Inspection Report(EIR) for it’s Aurangabad, India facility. The inspection was conducted by the US FDA between February 10, 2020 and February 14, 2020.
Nilesh Gupta, Managing Director, Lupin said, “We are delighted with the receipt of the EIR for Aurangabad classifying the inspection as No Action Indicated. This takes us a step forward in our efforts of enhancing our compliance and quality standards across all our manufacturing sites. We continue to work with the US FDA to continuously improve our quality and compliance while providing important medicines to the US market”.